Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial Journal Article
| Authors: | Rugo, H S.; Bardia, A.; Marmé, F.; Cortés, J.; Schmid, P.; Loirat, D.; Trédan, O.; Ciruelos, E.; Dalenc, F.; Gómez Pardo, P.; Jhaveri, K. L.; Delaney, R.; Valdez, T.; Wang, H.; Motwani, M.; Yoon, O. K.; Verret, W.; Tolaney, S. M. |
| Article Title: | Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial |
| Journal Title: | Lancet |
| Volume: | 402 |
| Issue: | 10411 |
| ISSN: | 0140-6736 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2023-10-21 |
| Start Page: | 1423 |
| End Page: | 1433 |
| Language: | English |
| DOI: | 10.1016/s0140-6736(23)01245-x |
| PROVIDER: | EBSCOhost |
| PROVIDER: | cinahl |
| PUBMED: | 37633306 |
| DOI/URL: | |
| Notes: | Accession Number: 173098527 -- Entry Date: In Process -- Revision Date: 20231025 -- Publication Type: Journal Article -- Journal Subset: Biomedical; Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer Reviewed; UK & Ireland -- NLM UID: 2985213R. -- Source: Cinahl |
